Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients

Sponsor
University of California, Davis (Other)
Overall Status
Completed
CT.gov ID
NCT01270854
Collaborator
Bayer (Industry)
46
1
2
14
3.3

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether an intravenous salt solution called "Plasmalyte" causes less abnormality of the body's acid levels than a solution called "Normal Saline."

Condition or Disease Intervention/Treatment Phase
  • Other: Plasmalyte A
  • Other: Normal Saline
N/A

Detailed Description

Electrolyte-containing intravenous fluids are routinely administered to patients in the first few hours after acute traumatic injury. Although Normal Saline (0.9% sodium chloride) is commonly used in this setting, it causes a hyperchloremic acidosis that may exacerbate metabolic derangements that occur after acute injury. Plasmalyte A is a solution that more closely matches physiologic electrolyte levels. In this study, we will evaluate whether Plasmalyte A results in less disturbance of the base deficit 24 hours following traumatic injury than does Normal Saline.

Study Design

Study Type:
Interventional
Actual Enrollment :
46 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients
Study Start Date :
Feb 1, 2011
Actual Primary Completion Date :
Feb 1, 2012
Actual Study Completion Date :
Apr 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: Plasmalyte

Administration of Plasmalyte A as the standard intravenous fluid during the first 24 hours after arrival to the hospital

Other: Plasmalyte A
Intravenous fluid

Active Comparator: Normal Saline

Administration of Normal Saline as the standard intravenous fluid during the first 24 hours after arrival to the hospital

Other: Normal Saline
Intravenous fluid

Outcome Measures

Primary Outcome Measures

  1. Change in the base deficit [24 hours after randomization]

    Base deficit at 24 hours after randomization minus the base deficit at randomization

Secondary Outcome Measures

  1. Mortality [Hospital discharge]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Triaged upon arrival to the hospital as severely injured

  • At least 18 years of age

  • Meets at least one of the following criteria:

  1. Intubated or likely to become intubated within 60 minutes of arrival at the hospital

  2. Likely to need an operation within 60 minutes of arrival

  3. Received or likely to receive a blood transfusion within 60 minutes of arrival

Exclusion Criteria:
  • Greater than 60 minutes since arrival at the hospital

  • Death likely within 48 hours

  • Transfer from another hospital

  • Pre-existing renal failure requiring dialysis

  • Pregnancy

  • Prisoner status

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of California, Davis, Medical Center Sacramento California United States 95817

Sponsors and Collaborators

  • University of California, Davis
  • Bayer

Investigators

  • Study Director: Garth H. Utter, MD, University of California, Davis
  • Principal Investigator: Lynette A. Scherer, MD, University of California, Davis

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of California, Davis
ClinicalTrials.gov Identifier:
NCT01270854
Other Study ID Numbers:
  • 200917793
First Posted:
Jan 5, 2011
Last Update Posted:
May 30, 2017
Last Verified:
May 1, 2017
Keywords provided by University of California, Davis
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 30, 2017